Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer ...
EMERYVILLE, Calif., February 09, 2026--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and ...
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including but not limited to those regarding the ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® ...
EMERYVILLE, Calif., February 03, 2026--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (Nasdaq: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and ...
Estrella Immunopharma, Inc. (Nasdaq: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancer and ...
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR® Estrella Immunopharma, Inc. (Nasdaq: ESLA) ...
One of the key ways to gather some experience and help you level up in Fallout 76 is to capture workshops. There are plenty of them scattered around the wastelands of Appalachia, and they are fairly ...
General Motors’ second joint venture in China, SAIC-GM-Wuling (SGMW), has just officially launched the all-new 2026 Wuling Starlight 560 in the Asian country. As such, the all-new 2026 Wuling ...
An independent Data Safety Monitoring Board (DSMB) confirms EB103’s favorable safety profile with no treatment-related serious adverse events (SAEs) even in high-risk patients who are ineligible for ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results